Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Data publikacji: 17 mar 2022

Zakres stron: 56 - 65

Otrzymano: 22 cze 2021

DOI: https://doi.org/10.2478/rjim-2021-0034

Słowa kluczowe

atypical hemolytic uremic syndrome, eculizumab, therapeutic plasma exchange, discontinuation, prognosis

© 2022 Hasan H. Yeter et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.